title: Risk sharing agreements: what lessons from Italy?
abstract: Italy is one of the few countries that have matured substantial experience of risk-sharing agreements so far. The first performance-based arrangement was agreed in July 2006, and as of October 2010, eighteen contracts have been in force.The complex management of discount schemes is entirely based on Web registries run by AIFA, the Italian drug agency. The system validates each prescription and automatically requests the hospital pharmacy by e-mail to release the drug. If a patient meets nonresponder criteria, the hospital pharmacist should apply for pay-back to the manufacturer. There are still some important question marks to address. First of all, nonresponders have to be documented by health authorities, otherwise any undocumented nonresponder will be paid as a success. Another question concerns pre-set timing. Although the scientific rationale of the nonresponder criteria for each drug has not been made public, time frames appear too short to allow a reliable assessment. Another question is whether regions, which are financially accountable in Italy for pharmaceutical expenditure, are really able to claw back refunds from manufacturers. Unfortunately here again there are no official figures, and regions do not seem yet able to quantify the amount of pay-back matured in the 4 previous years. The delayed and incomplete availability of pay-back procedures may be one explanation.
authors.affiliation: CESAV – Center for Health Economics, Mario Negri Institute for Pharmacological Research, Villa Camozzi, 20040 Ranica (BG), Italy. lgarattini@marionegri.it
authors.forename: Livio
authors.initials: L
authors.lastname: Garattini
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Casadei
mesh_terms: D004345:Drug Industry / Q000191:economics*; D006291:Health Policy / Q000191:economics; D006295:Health Resources / Q000191:economics; D006801:Humans; D007391:International Cooperation; D020407:Internet; D007558:Italy; D009313:National Health Programs / Q000191:economics; D017063:Outcome Assessment, Health Care / Q000191:economics; D055553:Prescription Drugs / Q000191:economics*; D018570:Risk Assessment / Q000379:methods; D020414:Risk Sharing, Financial / Q000191:economics*
chemical_list: D055553:Prescription Drugs